Compare RCI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCI | BBIO |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | Canada | United States |
| Employees | 24000 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 15.9B |
| IPO Year | N/A | 2019 |
| Metric | RCI | BBIO |
|---|---|---|
| Price | $34.54 | $82.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 25 |
| Target Price | $44.00 | ★ $86.33 |
| AVG Volume (30 Days) | 1.3M | ★ 3.0M |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $6.78 | $89.45 |
| Revenue Next Year | $1.45 | $73.78 |
| P/E Ratio | $4.12 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $31.38 | $45.42 |
| 52 Week High | $41.14 | $93.42 |
| Indicator | RCI | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 56.36 |
| Support Level | $31.87 | $78.98 |
| Resistance Level | $38.99 | $85.34 |
| Average True Range (ATR) | 0.78 | 2.27 |
| MACD | 0.15 | -0.65 |
| Stochastic Oscillator | 59.63 | 47.73 |
Rogers Communications is the largest wireless service provider in Canada with more than 11 million subscribers, equating to one-third of the total Canadian market. Rogers' wireless business accounts for more than half of total revenue and has been growing at a higher rate than other segments. The cable segment, which provides about 38% of total revenue after acquiring Shaw, offers home internet, television, and landline phone service to consumers and businesses. Remaining sales come from Rogers' media unit, which owns and operates various television and radio stations and major Toronto sports franchises, including the Blue Jays, Maple Leafs, Raptors, Toronto FC, and Argonauts.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.